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Purpose: Genetic and epidemiologic studies have shown that lipid genes and  High Density Lipoproteins 129 
(HDL) are implicated in age-related macular degeneration (AMD). We studied circulating lipid levels in 130 
relation to AMD in a large European dataset, and investigated whether this relationship is driven by 131 
certain sub fractions. 132 
Design: (Pooled) analysis of cross-sectional data. 133 
Participants: 30,953 individuals aged 50+ participating in the E3 consortium; and 1530 individuals from 134 
the Rotterdam Study with lipid sub fraction data. 135 
Methods: In E3, AMD features were graded per eye on fundus photographs using the Rotterdam 136 
Classification. Routine blood lipid measurements were available from each participant. Data on genetics, 137 
medication and confounders such as body mass index, were obtained from a common database. In a 138 
subgroup of the Rotterdam Study, lipid sub fractions were identified by the Nightingale biomarker 139 
platform. Random-intercepts mixed-effects models incorporating confounders and study site as a 140 
random-effect were used to estimate the associations. 141 
Main Outcome Measures: early, late or any AMD, phenotypic features of early AMD, lipid 142 
measurements.   143 
Results: HDL was associated with an increased risk of AMD, corrected for potential confounders (Odds 144 
Ratio (OR) 1.21 per 1mmol/L increase (95% confidence interval[CI] 1.14-1.29); while triglycerides were 145 
associated with a decreased risk (OR 0.94 per 1mmol/L increase [95%CI 0.91-0.97]). Both were 146 
associated with drusen size, higher HDL raises the odds of larger drusen while higher triglycerides 147 
decreases the odds. LDL-cholesterol only reached statistical significance in the association with early 148 
AMD (p=0.045). Regarding lipid sub fractions: the concentration of extra-large HDL particles showed the 149 
most prominent association with AMD (OR 1.24 [95%CI 1.10-1.40]). The CETP risk variant (rs17231506) 150 
for AMD was in line with increased-HDL levels (p=7.7x10-7); but LIPC risk variants (rs2043085, rs2070895) 151 




).  152 
Conclusions: Our study suggests that HDL-cholesterol is associated with increased risk of AMD and 153 
triglycerides negatively associated. Both show the strongest association with early AMD and drusen. 154 
Extra-large HDL sub fractions seem to be drivers in the relation with AMD, variants in lipid genes play a 155 
more ambiguous role in this association. Whether systemic lipids directly influence AMD or represent 156 
lipid metabolism in the retina remains a question to be answered.  157 
 158 
Word count: 350 159 
Keywords: Age-related macular degeneration , lipids, high-density lipoproteins, cholesterol, E3 160 














Age-related macular degeneration (AMD) is a leading cause of blindness in the developed world with 163 
10.4 million sufferers worldwide in 2015
1
. It is a multifactorial disease affecting the elderly involving 164 
genetics and lifestyle factors. The diagnosis of AMD is based on imaging of the retina with drusen as the 165 
hallmark of early disease, and chorioretinal neovascularization and atrophy of the retinal pigment 166 
epithelium (RPE) are indicative of late disease. The number of drusen and total drusen area are 167 
prominent predictors of progression of the early stages of AMD
2, 3
. 168 
Drusen are lipid-rich, protein-containing deposits that accumulate between the RPE and Bruch’s 169 
membrane. The accumulation of drusen shows resemblance to the formation of atherosclerotic 170 
plaques
4
 seen in cardiovascular disease, with a similar composition of proteins and protein complexes 171 
such as apolipoprotein (Apo)E, cholesterol esters and complement proteins.
5, 6
 The lipid load in drusen is 172 
as high as 40%
7
, and is thought to be partly derived from the systemic circulation. This triggered many 173 
studies to evaluate the relationship between serum or plasma lipids and AMD.
8-12
 Some found 174 
associations with various serum or plasma lipid levels and drusen or AMD
11-18
, but results were mainly 175 
weak and inconsistent. As a biological explanation is lacking, the relationship remains unsettled but 176 
intriguing.  177 
 Genetically, lipid metabolism is also involved in AMD. Genetic associations have been 178 
established for four genes encoding components of the HDL metabolism: ABCA1, CETP, APOE and LIPC19-179 
25
. The ATP-binding cassette (ABC) transporter A1 (ABCA1) is a cellular cholesterol efflux pump leading to 180 
formation of nascent HDL. ApoE, encoded by the APOE gene, facilitates cholesterol uptake by HDL. 181 
Cholesteryl transfer protein (CETP) exchanges cholesteryl esters and triglycerides between HDL and 182 
other lipoproteins, and thereby influences HDL particle size.
26
 Lastly, hepatic lipase encoded by the LIPC 183 
gene hydrolyzes triglycerides and phospholipids in lipoproteins
27
 and thereby partly converts very low 184 
density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) to low density lipoproteins 185 
(LDL)
20
 and plays a role in altering the HDL contents.   186 
 The European Eye Epidemiology (E3) consortium within the European EYE-RISK project enabled 187 
us to investigate the relationships between systemic lipids levels, lipid genes, and AMD using a very 188 
large data set. With nuclear magnetic resonance (NMR) spectroscopy we studied these relationships in 189 
















Study population: 194 
Routine blood lipid measurements 195 
Fourteen studies from France, Germany, Italy, the Netherlands, Norway, Portugal and United Kingdom 196 
participating in the E3 consortium enrolled in the current study (cohort descriptions available at External 197 
link http://www.aaojournal.org). E3 consists of European studies with epidemiologic data on common 198 
eye disorders; a detailed description on the studies included in the consortium has been published 199 
elsewhere.
28
 All studies with gradable macular fundus photographs (N=30,953 participants) aged 50 200 
years and over contributed their data to the EYE-RISK database version 4.0. Studies were population-201 
based cohort studies except for CRETEIL and EUGENDA which are clinic-based studies. Routine blood 202 
lipid measurements and AMD outcomes of the same visit were used for this analysis; for TwinsUK the 203 
closest visit to capturing of the retinal fundus photos was used. All studies were performed in 204 
accordance with the Declaration of Helsinki for research involving human subjects and the good 205 
epidemiological practice guideline.  206 
Detailed lipid analyses 207 
The population-based Rotterdam Study (RS) I provided data on lipid sub fractions which were 208 
determined at visit 4. Descriptive statistics of this cohort are shown in Supplementary Table 1 (available 209 
at External link http://www.aaojournal.org).  210 
 211 
Clinical examination: 212 
AMD features were graded per eye on fundus photographs by experienced graders or clinicians; the 213 
most severe AMD grade classified the AMD status of the person. When needed, photographs were 214 
regraded by expert graders from Moorfields Eye Hospital and the Rotterdam Study to harmonize the 215 
outcome. AMD status was determined for all included studies using the Rotterdam Classification as 216 
previously described.
29
 In brief, grade 0 or 1 are considered no AMD; grade 2 and 3 with soft indistinct 217 
drusen, reticular drusen or distinct drusen with pigmentary changes as early AMD, and grade 4 with 218 
Geographic Atrophy or Choroidal Neovascularization as late AMD. The area of the Early Treatment 219 
Diabetic Retinopathy Study grid covered by drusen was estimated in RS I visit 4 per grid circle, and 220 
calculated using previously defined harmonization criteria
30













including smoking habits were assessed by questionnaire; lipid measurements and other clinical 222 
determinants such as hypertension, body mass index (BMI), diabetes mellitus were examined at each 223 
individual research center (Supplement cohort descriptions available at External link 224 
http://www.aaojournal.org). Fasting blood draws were taken in all studies except for EUGENDA, MARS, 225 
and the Tromsø Eye Study, which drew blood samples non-fasting. Total cholesterol, HDL-cholesterol, 226 
LDL-cholesterol and triglycerides were measured in plasma (POLA, PAMDI, Montrachet-3C, CRETEIL) or 227 
in serum (remaining studies) using standard operating procedures. When LDL was not measured and 228 
triglycerides were below 4.52mmol/L, a proxy was calculated using the Friedewald formula31: LDL-229 
cholesterol  = Total cholesterol – HDL cholesterol – (Total triglyceride ÷ 2.19); only positive values 230 
entered the analysis.  231 
 232 
Nuclear magnetic resonance (NMR) metabolomics analysis 233 
Lipid sub fractions were measured with the Nightingale’s NMR-based biomarker platform in fasting 234 
Ethylenediaminetetraacetic acid (EDTA) plasma samples (Nightingale Ltd, Helsinki, Finland). These 235 
measurements cover multiple metabolic pathways, including lipoprotein lipids and subclasses, fatty 236 
acids, amino acids, and glycolysis-related metabolites. The NMR-based metabolic profiling has 237 
previously been described in detail
32
 and has been used in multiple large-scale epidemiological and 238 
genetic studies
33-36
.  239 
 240 
Genetic analyses  241 
The Alienor-3C study and Montrachet-3C study were genotyped with the Illumina Human 610-Quad 242 
BeadChip and imputed with the 1000 Genomes Phase I integrated variant set (March2012) using Shapeit 243 
v2.r727 (https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html) for pre-phasing and 244 
Impute2 v2.3 (https://mathgen.stats.ox.ac.uk/impute/impute_v2.html) for imputation. Rotterdam Study 245 
I, II and III were genotyped using the Illumina 550K, 550k due/610K Illumina arrays. The genotypes were 246 
imputed with the 1000 Genomes (Phase 1 version 3) reference panel using the Markov chain 247 
Haplotyping (MaCH)/minimac software
37-39
. The EUGENDA study was genotyped with a custom-designed 248 
Illumina HumanCoreExome array within the International AMD Genetics Consortium (IAMDGC). Details 249 















. All cohorts applied similar quality control procedures to genotype data 251 
prior to analysis, imputation quality was r
2
>0.3.  252 
A total AMD genetic risk score was calculated using 33 out of the 52 known AMD risk variants
19
 available 253 
in the EYE-RISK database version 4.0, see also subscript Supplementary Table 19 (available at External 254 
link http://www.aaojournal.org). Genetic allele dosage was annotated as 0 for non-carriers, 1 for 255 
heterozygotes, and 2 for homozygotes. The genetic risk score was composed by calculating the sum of 256 
the betas of independent risk variants. The score was standardized and added as a covariate in a linear 257 
regression analysis with AMD as the dependent variable. The linear regression was corrected for age, 258 
sex, lipid lowering drugs and study site. The effect of individual lipid-related single nucleotide 259 
polymorphisms (SNP) on each lipid level or lipid sub fraction was assessed in a mixed-effects regression 260 
correcting for age, sex, lipid lowering drug usage, plasma or serum, fasting state and using study site as a 261 
random effect term. The p-value threshold for these analyses were 0.05/60 = 0.00083 (8.3x10
-4
) after 262 
Bonferroni correction.    263 
Statistical analysis  264 
The outcome variable was presence of early or late AMD versus no AMD. Differences in baseline 265 
characteristics were evaluated with a Wald test using a logistic regression analysis, adjusting for age, 266 
gender, and study site. Analyses were conducted on complete data. Odds ratios (OR) for the routine 267 
blood lipid measurements were calculated using random-intercepts mixed-effects logistic regression 268 
models, including study site as a random effect term to allow for variability between study sites. The 269 
study site specific fixed effects estimates were transformed to their marginal counterparts as described 270 
by Heagerty and Zeger
40
.  271 
 272 
Association of HDL-cholesterol with AMD characteristics (presence of various drusen sizes, hyper- or 273 
hypopigmentation) were calculated in a univariate logistic regression analysis for the worse eye, defined 274 
as the eye with the most severe lesions of each AMD characteristic, correcting for age, sex, lipid 275 
lowering drugs usage and study site. The linear regression for HDL-cholesterol and drusen area was 276 
calculated in the Rotterdam Study I visit 4 only.  277 
For the analysis on lipid sub fractions, all sub fractions were +1 log transformed and scaled to make 278 
comparable measurements. Association magnitudes were reported in units of standard deviation (SD) or 279 
odds ratio (OR) change per 1-SD increase in each metabolite, as previously suggested by others
34, 35
. To 280 















 on the SNPSpD online interface
42
. Bonferroni correction was applied to correct for multiple 282 
testing using the eigenvalues to calculate the p-value threshold (p-value=0.001087). To test for 283 
differences between AMD stage and the mean of the lipid sub fractions, a Welch test was performed on 284 
the total of all age categories. The Welch test was chosen since homogeneity of variance was violated 285 
between the AMD severity classes. The post hoc Games-Howell test was used to investigate differences 286 
between the mean of the No AMD and Late AMD groups. 287 
   288 
Mixed-effects logistic regression models were performed with R package lme443 and mixed-effects 289 
regression models with nmle
44
 (R Core Team (2016). R: A language and environment for statistical 290 
computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/); 291 
Welch-test and genetic risk scores with SPSS (IBM Corp. Released 2012 IBM SPSS Statistics for Windows, 292 
Version 24.0 Amonk, NY: IBM Corp). Graphical outputs were constructed with GraphPad Prism 7 293 




We identified a total of 4,730 individuals with early AMD; 2,441 with late AMD; and 23,782 non-affected 298 
persons. The baseline characteristics of these participants are summarized in Table 2. AMD cases and 299 
controls differed in age, sex, BMI, lipid lowering drug use, and smoking, in accordance with the known 300 
AMD risk profile.  301 
Routine blood lipid measurements and AMD in the E3 consortium 302 
Next, we examined lipid levels in the entire study population. Mean levels of all lipids were within 303 
physiologic limits: mean total cholesterol ranged between studies from 5.1 mmol/L to 5.8 mmol/L; mean 304 
HDL-cholesterol  from 1.4 mmol/L to 1.9 mmol/L. Mean LDL-cholesterol ranged from 3.0 mmol/L to 3.8 305 
mmol/L; and mean triglycerides from 1.2 mmol/L to 1.7mmol/L. A fifth of the study population had 306 
collected only non-fasting blood samples; in these, the mean levels were similar but on the higher range 307 
of total cholesterol and triglycerides; 5.7 mmol/L for total cholesterol and 1.7mmol/L for triglycerides. 308 
Mean HDL-cholesterol was on the lower range with 1.5mmol/L and LDL-cholesterol was very 309 













 Table 3 shows the association between lipid levels and AMD adjusted for age, sex, lipid lowering 311 
drug usage, body mass index, smoking, plasma or serum, fasting state and study site in the E3 312 
consortium. Analyses for late AMD were also corrected for diabetes. Total cholesterol was not 313 
associated with any of the AMD outcomes. Higher HDL-cholesterol was associated with an increased risk 314 
of any AMD, and risk estimates were slightly higher for early AMD (OR 1.34 per 1 mmol/L increase), than 315 
for late AMD (OR 1.12 per 1 mmol/L increase), but had overlapping confidence intervals. LDL-cholesterol 316 
and triglycerides were inversely associated with early (OR 0.96 and OR 0.88 per 1 mmol/L increase, 317 
respectively) and any AMD (OR 0.98 and OR 0.94 per 1 mmol/L increase, respectively), but effect sizes 318 
were smaller than for HDL-cholesterol. Sensitivity analysis on fasting and non-fasting sampling methods 319 
and sex showed no interaction or it showed interaction but with similar point estimates of the odds 320 
ratios which made sampling effect or confounding unlikely. However, a sensitivity analysis on plasma or 321 
serum sampling methods did show a change in direction of effect of triglycerides measured in plasma, 322 
although not statistically significant (Supplementary Table 4-10, available at External link 323 
http://www.aaojournal.org). To investigate whether observed associations were the result of 324 
preferential survival of elderly without cardiovascular disease, we repeated the analyses in various age 325 
strata (Supplementary Table 11-13, available at External link http://www.aaojournal.org). Even in those 326 
aged 65 years or younger with AMD, HDL-cholesterol was significantly associated with increased risk of 327 
AMD (OR 1.19 per 1 mmol/L increase, p-value 0.02). LDL-cholesterol was inversely associated with AMD 328 
(OR 0.93 per 1 mmol/L, p-value 0.02), associations with triglycerides became insignificant.  329 
 330 
Routine blood lipids measurements and early AMD phenotype  331 
As the association between HDL-cholesterol and AMD was most pronounced in those with early AMD, 332 
we performed more detailed analyses using the various early AMD features as outcomes. Effects of HDL-333 
cholesterol and triglycerides became larger with increasing drusen size, Figure 1. Likewise, higher HDL 334 
levels were associated with greater drusen area  (beta 0.014; P-value=0.001); higher triglyceride levels 335 
were associated with lower drusen area. Correcting for smoking did not change these results (data not 336 
shown). Lipids were not statistically significantly associated with pigmentary changes, and total 337 
cholesterol and LDL-cholesterol were not associated with any early AMD characteristic (Supplementary 338 














Lipid sub fractions in the Rotterdam Study 341 
To explore whether the association between HDL-cholesterol, triglycerides, and AMD was driven by 342 
specific lipid sub fractions, we examined lipid sub fractions with NMR in the Rotterdam Study-I Figure 2 343 
(Supplementary table 14, available at External link http://www.aaojournal.org). The concentration of 344 
extra-large HDL particles (XL-HDL-P) was most significantly associated with any AMD, particularly the sub 345 
fractions of phospholipids and total lipids within extra-large HDL particles. These sub fractions are highly 346 
correlated (Pearson correlation >0.97). Next, total cholesterol and free cholesterol in the small VLDL 347 
were significantly associated, as well as the ratio ApoB:ApoA1, with a Pearson correlation ranging 348 
between 0.93 and 0.87. No other metabolites were significantly associated with AMD. Correcting for 349 
smoking did not change these significant results (data not shown). The ApoB-ApoA1 ratio is a surrogate 350 
for the LDL/HDL ratio with a small ratio suggesting a high level of HDL compared to LDL lipoproteins.  351 
These associations show a dose dependent relation with AMD stages from the Rotterdam Classification 352 
Figure 3. To test if the mean of the lipid sub fractions per AMD stage differed statistically, we performed 353 
a Welch test, which was significant for each of the six sub fractions. The sub fractions related to HDL also 354 
showed a statistically significant difference in the Games-Howell post hoc test comparing the mean of 355 
those with no AMD with late AMD; p-value=0.01 for the concentration of extra-large HDL, p-value=0.02 356 
for phospholipids in extra-large HDL and the p-value=0.01 for total lipids in extra-large HDL. The Games-357 
Howell post-hoc test was not significant in the other three sub fractions, likely due to the small group 358 
size and variance in late AMD. (Supplementary Figure 4 shows dose dependency per age category 359 
available at External link http://www.aaojournal.org.) 360 
We also performed the analyses stratified for lipid-lowering drug use, which was reported by 361 
less cases (17.0%) than controls (24.2%) in the Rotterdam Study (p=0.02). Significance was found only in 362 
those not taking lipid-lowering drugs, and point estimates were highly similar to the overall group. 363 
(Supplementary Table 17- 18, available at External link http://www.aaojournal.org).  364 
 365 
Lipid genes, lipid sub fractions and AMD 366 
As genetic variants are an important cause of AMD, we investigated the relation between genes, lipids, 367 
and AMD. First, we investigated whether a genetic risk score with 33 SNPs covering all major AMD genes 368 
influenced lipid levels in the E3 consortium, and found with increasing genetic risk also an increase of 369 
HDL-cholesterol (p=0.03)  (Supplementary Table 19 available at External link 370 













CETP variant rs17231506 was positively associated with HDL-cholesterol levels and negatively associated 372 
with LDL-cholesterol, while both LIPC variants rs2043085 and rs2070895 were inversely associated with 373 
HDL-cholesterol. In addition, the APOE variant rs429358 was associated with decreased levels of total 374 
cholesterol, triglycerides, and LDL-cholesterol, but with increased levels of HDL-cholesterol. APOE 375 
variant rs73036519 had no significant effect on the routine lipid measurements or on the lipid sub 376 
fractions. ABCA1 variant rs2740488 only influenced total cholesterol (Table 20A). When restricting the 377 
analysis to lipid sub fractions in the Rotterdam Study (Table 20B), we found similar results for the CETP 378 
variant and the LIPC variants with all extra-large HDL sub fractions.  379 
 380 
DISCUSSION 381 
Routine blood lipid measurements 382 
Based on pooled data of 30,953 participants from Western Europe, we have shown that high circulating 383 
HDL-cholesterol levels and low triglyceride levels are significantly associated with AMD. The magnitude 384 
of the effect was higher for early than for late AMD, and associations were related to drusen size and 385 
area. By focusing on lipid sub fractions, we revealed that extra-large HDL particles, small VLDL particles, 386 
and the ApoB-ApoA1 ratio, a surrogate for the LDL/HDL ratio, were dose-dependent drivers of this 387 
association. AMD risk variants in lipid genes did not provide a clear explanation, as in particular the 388 
variants in LIPC which increase the risk of AMD, decreased HDL-cholesterol in the systemic circulation. 389 
Our results should be interpreted in light of the strengths and limitations of the study. The combined 390 
efforts of two European consortia enabled us to create a very large database providing the statistical 391 
power to resolve conflicting findings from previous studies. The detailed NMR lipid analysis in a subset 392 
created the opportunity to find the metabolic profile behind the lipid associations. A weakness of the 393 
consortium was the use of different protocols for blood sampling, definition of confounders, and AMD 394 
phenotyping. We addressed this issue by performing a stratified analysis on sampling methods, and 395 
found that only the associations for triglycerides changed direction of effect for plasma, albeit non-396 
significantly. We harmonized all confounders as well as the criteria for early and late AMD, and 397 
corrected for study site in the mixed-effect models.  398 
Many previous studies did not find a statistically significant association between lipids and AMD, but 399 













inverse association with triglycerides
13
. The current pooled study showed that the levels of these lipids 401 
were within physiological range in both cases and controls, and that absolute differences were small in 402 
mmol/L. However, our data suggest that an increase of HDL from the 25th percentile to the 75th 403 
percentile coincides with an AMD risk increase of about 20%. Selective survival does not appear to 404 
explain our findings, as the association was already present in the youngest age group (<= 65 yrs).  The 405 
exact clinical interpretation remains to be defined. Nevertheless, the findings contribute to the 406 
understanding of AMD pathogenesis.  407 
Animal research has provided some key insights in retinal lipid metabolism. Studies in rodents showed 408 
that most lipids in the retina are synthesized locally and up to a quarter is derived from the systemic 409 
circulation
45. 
Another study in mice showed that a high fat diet increases cholesterol in the retina, but 410 
not as much as in the circulation. These results suggest that transport from the systemic circulation to 411 
the retina does take place, albeit modestly.
 
Although LDL delivers cholesterol most efficiently from the 412 
systemic circulation to the retina, HDL-cholesterol, with ApoA-I as its major lipid component
46
, does this 413 
as well via scavenger receptors
26, 47, 48
. The RPE processes the internalized lipids and subsequently 414 
secretes them again on the apical side via ABCA1 transporters into the inter-photoreceptor matrix. 415 
Thereafter, lecithin-cholesterol acyltransferase (LCAT), located at the surface of nascent HDL
49
, converts 416 
free cholesterol into esterified cholesterol,
50
 which are present in nascent HDL. In this way LCAT 417 
transforms nascent HDL into larger, mature HDL, while LIPC hydrolyzes phospholipids in the HDL 418 
lipoprotein
23, 51
. As suggested by Tserentsoodol et al
26
, due to the absence of LDL in the retina, it is 419 
possible that CETP has a role in transferring esterified cholesterol between lipoproteins or 420 
photoreceptor membranes. In the inter-photoreceptor matrix, HDL functions as a transport vehicle 421 
between the RPE and the photoreceptors supporting the high synthesis and degradation of the lipid-rich 422 
photoreceptor disks
26
. The RPE maintains the lipid balance by transporting lipoproteins back to Bruchs 423 
membrane
52
. The lipid contents of these lipoproteins resemble that of LDL lipoproteins rather than HDL 424 
as it has a high abundance of esterified cholesterol, but both ApoA and ApoB
53
. It has been proposed 425 
that this large amount of esterified cholesterol acts as a barrier for lipid transport through an aging 426 
retina, thereby facilitating the formation of deposits
54
. Another mechanism proposed to form deposits is 427 
through the impairment of ABCA1 transporter of macrophages, which impairs the efflux of free 428 
cholesterol out of the macrophage. This results in senescent macrophages with high levels of cholesterol 429 
in the retina of mice
55













Interestingly, lipoproteins appear to be closely related to the complement system, the major pathway in 431 
AMD pathogenesis. Proteomic studies have shown that HDL-lipoproteins can contain essential 432 
complement components, such as C1, C2, C3, C5 and Factor B
56-58
. One study showed that CFH and 433 
lipoproteins have competitive binding in the sub-RPE extracellular matrix, when CFH is low lipoproteins 434 
can accumulate sub-RPE
59
. By contrast, HDL can also carry complement regulators such as FH1, CFHR4 435 
and CFHR5
60, 61
. ApoA-I attached to HDL can bind clusterin, a complement lysis inhibitor that stops the 436 
complement cascade just before the C5b-9 complex is inserted into the target
62
. These findings suggest 437 
that HDL is involved in pro-inflammatory as well as complement inhibitory tasks. Higher HDL levels may 438 
cause imbalance of the physiological homeostasis
8, 63
. Taken together, this plethora of biological leads 439 
supports the contention that HDL may play a role in the initiation of AMD. More comprehensive 440 
research into lipid metabolism in the retina is warranted.  441 
In our study, we found elevated levels of HDL-cholesterol in the circulation and decreased levels of 442 
triglycerides in persons with AMD. In more detailed analysis, we observed a higher concentration of 443 
extra-large HDL particles with a higher total lipid and phospholipid content, which are under genetic 444 
control of CETP and LIPC. The high phospholipid content of extra-large HDL is very likely related to the 445 
larger particle size, since phospholipids compose the outer shell of the lipoprotein.  CETP may exert its 446 
effect on AMD partly through systemic HDL, in line with previous Mendelian randomization studies
24, 66
. 447 
The opposing effects which we found for LIPC are less easily explained, but have been observed by 448 
others
23, 24
. This finding suggests that systemic HDL may be a biomarker rather than directly causally 449 
related to AMD. In a larger study, Kettunen et al33 found more genetic effects on lipid sub fractions; 450 
variants in CETP and APOE also had a decreasing effect on the small VLDL sub fractions, while a variant 451 
in ABCA1 increased extra-large HDL. Our smaller sample size hampered us to replicate these findings.  452 
 453 
Where do these lipid associations fit in the chronology of AMD development? The more pronounced risk 454 
for early AMD and increasing odds ratios of HDL-cholesterol for the larger size drusen suggests that 455 
lipids play an important role at the early phase of disease. Hypothetically, intervention at this phase 456 
would be most promising in preventing blindness. We did not find statistical significance for any lipid 457 
sub fraction in only those using lipid-lowering drugs, possibly because there is no effect, but probably 458 
due to the lower power in this subgroup. Evidence from other studies indicate that statins increase HDL 459 
levels slightly
67 
 but reduce extra-large HDL
68
, and that HDL protein composition may change as well
69
. 460 
Most epidemiologic studies do not find any effect of lipid lowering drugs on AMD
8, 70-72
; however, one 461 















.  Large randomized controlled trials with long term follow-up are needed to clarify the relation 463 
between lipid lowering drugs and AMD.   464 
 465 
In conclusion, this study showed that HDL-cholesterol and triglycerides levels are particularly associated 466 
with early AMD, mostly through the association with drusen. Extra-large HDL sub fractions seem to be 467 
drivers of this association. Whether systemic lipids directly influence lipid metabolism in the retina or 468 




FIGURE LEGENDS 473 
Figure 1. Association of HDL-cholesterol and triglycerides with age-related macular degeneration 474 
characteristics 475 
Figure 2. The association of metabolic variables and AMD.  476 
Each bar represents the association with AMD, the size of the bar is the odds ratio, coloring refers to 477 
effect direction and significance. Dots indicate Bonferroni statistically significant metabolic variables 478 
corrected for age, sex and lipid lowering drugs. Labels describe the properties measured in each lipid 479 
sub fraction (P, concentration of particles; L, total lipids; PL, phospholipids; C, total cholesterol; CE, 480 
cholesterol esters; FC, free cholesterol; TG, triglycerides). List of abbreviations is in the annex.  481 
 482 
Figure 3. Stage dependent relationship of the six associated lipid sub fractions with AMD.  483 













Précis: (max 35 words)  
HDL-cholesterol is positively associated with AMD and triglycerides negatively. This is most 
prominently seen in drusen as early AMD features. This association seems to be driven by larger HDL 
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N=1066  Cases N=464  p‐value  OR  95% CI 
Sex, % female  55.5% (N=592)  57.5% (N=267)  0.83  1.03  0.82 ‐ 1.29 
Age (years)  74.7 (SD 5.9)  78.1 (SD 6.6)  <0.0001  1.09  1.07 ‐ 1.11 



















Hypertension %  85.7% (N=911)  88.4% (N=410)  0.83  0.96  0.68 – 1.36 
Diabetes  15.4% (N=152)  15.6% (N=68)  0.86  0.97  0.70 – 1.34 















Table 2. Baseline data and results of logistic regression analysis of the fourteen European studies.  




   
N = 4730 
N = 2441 
   
Sex, % female Early  61.7% (N=2918) <0.0001 1.21 1.13 - 1.29 
 Late  59.4% (N=1449) 0.74 0.98 0.88 – 1.10 
 Any 57.5% (N=13680) 60.9% (N=4367) <0.0001 1.15 1.09 - 1.23 
Age (years) Early   72.7 (SD 8.4) <0.0001 1.06 1.06 – 1.06 
 Late   76.9 (SD 8.1) <0.0001 1.12 1.11 – 1.13 
 Any 68.1 (SD 8.7) 74.1 (SD 8.5) <0.0001 1.08 1.07 - 1.08 
BMI Early   26.6 (SD 4.2) 0.008 0.99 0.98 – 1.00 
 Late   26.4 (SD 4.0) <0.0001 1.03 1.02 – 1.05 














0.94 – 1.09 














1.31 - 1.75 

















1.01 - 1.17 
1.22 - 1.53 
Hypertension % Early   48.7% (N=2153) 0.30 1.04 0.97– 1.12 
 Late   45.3% (N=977) 0.84 1.01 0.90 – 1.14 
 Any 49.0% (N=11010) 47.6% (N=3130) 0.43 1.03 0.96 - 1.10 
Diabetes Early   9.7% (N=435) 0.35 0.95 0.84 – 1.06 
 Late   13.2% (N=284) 0.002 1.33 1.11 – 1.58 
 Any 10.7% (N=2408) 10.8% (N=719) 0.70 1.02 0.92 - 1.13 
Lipid lowering drugs Early   24.7% (N=1084) 0.006 0.89 0.83 – 0.97 
 Late  22.5% (N=459) 0.86 0.99 0.85 – 1.14 
 Any 24.5% (N=5492) 24.0% (N=1543) 0.004 0.90 0.83 - 0.97 
Odds ratios are corrected for age, sex and study site. AMD = age-related macular degeneration, BMI= 

































OR for 1 
mmol/L 
increase 


























































3.45 (2.79-4.14)  
N=1580 





3.39 (2.74-4.07)  
N=5337 























0.94 0.91-0.97 2.35 x10
-5
 
Odds ratio estimates and 95% confidence intervals of lipid on early, late or any AMD after adjusting 
for age, sex, lipid lowering drug usage, body mass index, smoking, plasma or serum, fasting state and 
study site. Late AMD was also corrected for diabetes.  

















Interaction term  OR  95% CI  p‐value 
































































































Interaction term  OR  95% CI  p‐value
Total Cholesterol * 
plasma serum  0.97  0.90 – 1.04  0.43 
HDL‐cholesterol 
*plasma serum  1.03  0.85 – 1.25  0.77 
LDL‐cholesterol 
*plasma serum  0.98  0.89 – 1.06  0.56 
Triglycerides 














































































































































































Interaction terms  OR  95% CI  p‐value 
Total Cholesterol 
*gender  0.96  0.92‐1.01  0.11 
HDL‐cholesterol * 
gender  1.08  0.95‐1.22  0.24 
LDL‐cholesterol * 
gender  0.95  0.91‐1.001  0.053 
Triglycerides * 
































































































































Lipid sub fraction  p‐value OR 95%CI
Concentration extra‐large HDL   4.06x10‐4 1.24 1.10‐1.40
Phospholipids in extra‐large HDL   4.32x10‐4 1.24 1.10‐1.40
Total cholesterol in small VLDL   7.36x10‐4 0.81 0.72‐0.92
Ratio ApoB ApoA1  7.65x10‐4 0.82 0.730.92
Total lipids in extra‐large HDL   7.77x10‐4 1.23 1.10‐1.39
Free cholesterol in small VLDL   7.80x10‐4 0.81 0.72‐0.92
Total cholesterol in extra‐large HDL   1.40x10‐3 1.22 1.08‐1.37
Cholesterol esters in extra‐large HDL   1.50x10‐3 1.22 1.08‐1.37
Cholesterol esters in small VLDL   1.56x10‐3 0.82 0.73‐0.93





















































































































Variable  p‐value OR 95%CI 
Pyruvate(mmol/l)  0.005835 0.66 0.49‐0.8
Albumin(signal area)  0.00821 0.69 0.52‐0.90
Alanine(mmol/l)  0.013313 0.70 0.52‐0.92
Tyrosine(mmol/l)  0.04998 0.76 0.57‐0.99
Total lipids in small HDL  0.058837 0.76 0.57‐1.01
Concentration of small HDL particles  0.060846 0.76 0.57‐1.01
Diacylglycerol(mmol/l)  0.126999 0.80 0.60‐1.05
Lactate(mmol/l)  0.136759 0.81 0.61‐1.06
Triglycerides in extra large HDL  0.139265 1.22 0.94‐1.60

















Variable  p‐value OR 95%CI
Total cholesterol in small VLDL   0.000806 0.796 0.695‐0.908
ApoB ‐ ApoA1 Ratio  0.000808 0.802 0.705‐0.912
Phospholipids in extra‐large HDL   0.001003 1.246 1.093‐1.422
Concentration of extra‐ large HDL   0.001074 1.243 1.091‐1.416
Total lipids in extra small  VLDL   0.00109 0.801 0.700‐0.914
Free cholesterol in small VLDL   0.001098 0.802 0.701‐0.914
Total cholesterol in extra small VLDL   0.001122 0.803 0.703‐0.915
Concentration of extra small VLDL   0.001232 0.803 0.702‐0.916
Cholesterol esters in small VLDL   0.001387 0.804 0.702‐0.918



















Total cholesterol  ‐0.019 0.015 0.188
HDL‐cholesterol  0.012 0.005 0.031
LDL‐cholesterol   ‐0.025 0.013 0.056






























Table 20A. Mixed-effects linear regression model estimating the effect of SNPs on routine lipid measurements.  
Lipid 
CETP rs17231506 
Risk allele T, 
reference allele C 
LIPC rs2043085 
Risk allele C, 
reference allele T 
LIPC rs2070895 
Risk allele G, 
reference allele A  
APOE rs429358 
Risk allele T, 
reference allele C  
APOE rs73036519 
Risk allele G, 
reference allele C  
ABCA1 rs2740488 
Risk allele A, 
reference allele C  
Total cholesterol 
0.03 (p=0.07)   -0.019 (p=0.16) -0.04 (p=0.008) -0.18 (p< 0.0001) 0.01 (p=0.55) 0.06 (p=0.0002) 
HDL-cholesterol 
0.08 (p< 0.0001) -0.04 (p< 0.0001) -0.05 (p< 0.0001) 0.03 (p< 0.0001) -0.007 (p=0.24) 0.03 (p=0.0001) 
LDL-cholesterol 
-0.05 (p=0.0001) 0.02 (p=0.09) 0.004 (p=0.77) -0.19 (p< 0.0001) 0.01 (p=0.67) 0.04 (p=0.01) 
Triglycerides 
-0.025 (p=0.04) 0.001 (p=0.93) -0.006 (p=0.66) -0.06 (p=0.0004) 0.03 (p=0.03) 0.004 (p=0.78) 
Betas are corrected for age, gender, lipid lowering drugs, plasma or serum, fasting state and study site. Betas indicate the effect of the risk allele versus the 
reference allele. Bonferroni: 0.05/60 = 0.00083 (8.3x10-4). Red is negative effect size, blue is positive effect size.  
Table 20B. Linear regression model estimating the effect of SNPs on lipid sub fraction.  
Lipid 
CETP rs17231506 
Risk allele T, reference 
allele C  
LIPC rs2043085 
Risk allele C, 
reference allele T  
LIPC rs2070895 
Risk allele G, 
reference allele A  
APOE rs429358 
Risk allele T, 
reference allele C  
APOE rs73036519 
Risk allele G, reference 
allele C  
ABCA1 rs2740488 
Risk allele A, reference 





) -0.14 (p= 1.00x10
-6
) -0.13 (p= 1.55x10
-4





) -0.13 (p= 4.0x10
-6
) -0.13 (p= 1.04x10
-4
) -0.03 (p= 0.479) 0.04 (p=0.233) 0.03 (p=0.349) 
Total cholesterol 
in small VLDL 
-0.09 (p=0.003) -0.09 (p=0.003) -0.08 (p=0.02) -0.05 (p=0.294) -0.02 (p=0.631) 0.08 (p=0.027) 
Ratio ApoB ApoA1 
-0.10 (p=0.002) 0.004 (p=0.897) -0.003 (p=0.936) -0.09 (p=0.037) -0.04 (p=0.250) 0.02 (p=0.521) 








) -0.08 (p=0.056) 0.04 (p=0.213) 0.05 (p=0.138) 
Free cholesterol in 
small VLDL 
-0.08 (p=0.01) -0.08 (p=0.005) -0.09 (0.009) 0.01 (p=0.784) -0.03 (p=0.434) 0.07 (p=0.058) 
 





































































HDL-cholesterol is positively associated with AMD and triglycerides negatively. This is most 
prominently seen in drusen as early AMD features. This association seems to be driven by larger 
HDL sub fractions and HDL related genetics. 
